Integrated functional, gene expression and genomic analysis for the identification of cancer targets.
The majority of new drug approvals for cancer are based on existing therapeutic targets. One approach to the identification of novel targets is to perform high-throughput RNA interference (RNAi) cellular viability screens. We describe a novel approach combining RNAi screening in multiple cell lines...
Enregistré dans:
Auteurs principaux: | Elizabeth Iorns, Christopher J Lord, Anita Grigoriadis, Sarah McDonald, Kerry Fenwick, Alan Mackay, Charles A Mein, Rachael Natrajan, Kay Savage, Narinder Tamber, Jorge S Reis-Filho, Nicholas C Turner, Alan Ashworth |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fe6d4e18e3ac4117937a53debf5472d2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
NLK is a novel therapeutic target for PTEN deficient tumour cells.
par: Ana M Mendes-Pereira, et autres
Publié: (2012) -
Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.
par: Louise J Barber, et autres
Publié: (2011) -
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.
par: Stephen J Pettitt, et autres
Publié: (2013) -
A modified method for whole exome resequencing from minimal amounts of starting DNA.
par: Iwanka Kozarewa, et autres
Publié: (2012) -
Africa's 32 cents solution for HIV/AIDS.
par: Peter J Hotez, et autres
Publié: (2009)